Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?

被引:1
|
作者
Johnson, Gillian G. [1 ,2 ]
Carr, Daniel F. [3 ]
Pirmohamed, Munir [3 ]
Pettitt, Andrew R. [2 ]
机构
[1] Royal Liverpool & Broadgreen Univ Hosp Trust, Dept Haematol, Liverpool, Merseyside, England
[2] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool L69 3BX, Merseyside, England
[3] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L69 3BX, Merseyside, England
基金
英国医学研究理事会;
关键词
adverse drug reactions; bendamustine; chronic lymphocytic leukemia; cyclophosphamide; fludarabine; personalized medicine; pharmacogenomics; GENETIC-POLYMORPHISM; UNTREATED PATIENTS; HUMAN LIVER; RITUXIMAB; CYCLOPHOSPHAMIDE; BENDAMUSTINE; CHLORAMBUCIL; FLUDARABINE; EXPRESSION; VARIANTS;
D O I
10.2217/pgs.14.60
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
[No abstract available]
引用
收藏
页码:897 / 900
页数:4
相关论文
共 50 条